


Linvencorvir

Chemical Properties

CAS No. :	1808248-05-6
Formula:	C ₂₉ H ₃₅ FN ₆ O ₅ S
Molecular Weight:	598.69
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Linvencorvir (RG7907) belongs to HBV core protein allosteric modulators (CpAM) and is an orally active HBV core protein inhibitor with potent anti-HBV activity, low CYP3A4 induction, and good metabolic stability. This compound is used for the treatment of chronic hepatitis B virus infection.
Targets(IC50)	Apoptosis, Antibiotic, HBV
In vitro	<p>Methods: In HepG2.2.15 cells, treatment with different concentrations of Linvencorvir was performed to detect HBV DNA replication levels.</p> <p>Results: Linvencorvir inhibited HBV DNA replication with an EC₅₀ of 62 nM. [1]</p> <p>Methods: In HepG2.117 cells, treatment with different concentrations of Linvencorvir was performed to detect HBV DNA production levels.</p> <p>Results: Linvencorvir inhibited HBV DNA production with an EC₅₀ of 64 nM. [2]</p>
In vivo	<p>Methods: In the AAV-HBV mouse model, oral administration of Linvencorvir (20 mg/kg, once daily) was given for 70 consecutive days, and serum and liver virological indicators as well as liver injury markers were detected.</p> <p>Results: Linvencorvir significantly reduced serum HBsAg, HBeAg, and liver AAV-HBV episome levels, induced hepatocyte apoptosis and proliferation, accompanied by transient ALT elevation.[2]</p> <p>Methods: In the AAV-HBV mouse model, oral administration of Linvencorvir (6-20 mg/kg, once daily) was given for 8 consecutive weeks, and serum HBV DNA, HBsAg, and HBeAg levels were detected.</p> <p>Results: Linvencorvir dose-dependently reduced serum HBV DNA, HBsAg, and HBeAg levels.[3]</p>

Solubility Information

Solubility	DMSO: 128.8 mg/mL (215.14 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6703 mL	8.3516 mL	16.7031 mL
5 mM	0.3341 mL	1.6703 mL	3.3406 mL
10 mM	0.167 mL	0.8352 mL	1.6703 mL
50 mM	0.0334 mL	0.167 mL	0.3341 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Vanrusselt H, et al. Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles. *J Virol.* 2023 Oct 31;97(10):e0072223.

Kum DB, et al. Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation. *Hepatology.* 2023 Oct 1;78(4):1252-1265.

Zhang W, et al. Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection. *J Med Chem.* 2023 Mar 23;66(6):4253-4270.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481